Sobi launch Doptelet® (avatrombopag) in Europe
The UK will be the first country for launch for this thrombopoietin receptor agonist that is approved for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
Source:
Biospace Inc.
SPS commentary:
NICE has approved avatrombopag, within its marketing authorisation, as an option for treating severe thrombocytopenia (i.e. platelet count <50,000 per microlitre of blood).